The evolution of therapies for the treatment of multiple myeloma and related plasma cell dyscrasias has succeeded in transforming myeloma into a chronic disease. Conventional chemotherapy has been widely superseded by novel more targeted approaches impacting both the tumor cell and the microenvironment in which it resides. The seven chapters of this book highlight these advances and tackle the current landscape of therapies available to patients. The role of stem cell transplantation in the era of these novel agents is discussed, together with novel approaches under evaluation in early phase trials. This book provides a succinct overview of the evolving treatment paradigm of therapies in myeloma and will provide the reader with the context for use of such therapies.